间充质干细胞（mesenchymal stem cells，MSCs）是一种具有自我更新及多向分化潜能的干细胞。MSCs具有对多种肿瘤组织归巢及定向迁移的特性，可以将其作为治疗肿瘤药物的载体，用来治疗无法通过手术去除的肿瘤；同时，MSCs自身参与重塑肿瘤微环境，影响其侵袭、增殖和转移等生物学行为，并且具有抗炎及损伤组织修复的能力。肿瘤坏死因子相关凋亡配体（TRAIL/Apo2L）作为诱导细胞凋亡的肿瘤坏死因子家族成员之一，可通过结合肿瘤细胞表面两个特异性死亡受体（DR4、DR5），特异激活肿瘤细胞凋亡。TRAIL基因修饰的MSCs（TRAIL-MSCs）可定位至肿瘤组织并抑制原发肿瘤及转移瘤的增殖、促进其凋亡，有望用于多种实体肿瘤及血液肿瘤的靶向治疗。综述了TRAIL-MSCs治疗肿瘤的研究进展，并讨论了TRAIL-MSCs联合放化疗对肿瘤的治疗效果，为该疗法在肿瘤治疗领域的应用提供理论依据。
Mesenchymal stem cells (MSCs) is one of adult stem cells with self-renewal and multi-differentiation potential. MSCs also possess other characteristics including homing and directional migration to a variety of tumor tissues, which can be used as a vehicle for anti-tumor drug to treat the tumors which cannot be removed by surgery. Meanwhile, MSCs participate in reshaping the tumor microenvironment, affecting their biological behaviors such as invasion, proliferation and metastasis, and have the ability to anti inflammation and repair damaged tissues, thus laying the foundation for development of tumor drug. Tumor necrosis factorrelated apoptosis ligand (TRAIL/Apo2L), as one of the tumor necrosis factor family, which can specifically induces tumor cells apoptosis by binding with two specific death receptors (DR4, DR5) on the surface of tumor cells. Studies have found that engineered mesenchymal stem cells over-expressing TRAIL (TRAIL-MSCs) migrate to tumor tissue to reduce the growth of primary cancers and metastases, and promote the tumor cells apoptosis. So TRAIL-MSCs can be used as to treat a variety of solid tumors and hematological tumors. This paper reviewed the research progress of TRAIL-MSCs in the treatment of tumor, and discussed the therapeutic effect of TRAIL-MSCs combined with radiotherapy and chemotherapy on tumor, providing theoretical basis for the application of trail-MSCs in the field of tumor treatment.